Rafael (NYSE:RFL) Upgraded at Wall Street Zen

Rafael (NYSE:RFL) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings upgraded shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rafael has an average rating of “Sell”.

Rafael Stock Performance

Shares of NYSE RFL opened at $2.11 on Friday. The firm’s 50 day moving average price is $2.16 and its 200-day moving average price is $1.58. The company has a market cap of $109.72 million, a PE ratio of -3.10 and a beta of 0.29. Rafael has a 52-week low of $1.12 and a 52-week high of $3.96.

Institutional Investors Weigh In On Rafael

Several large investors have recently bought and sold shares of RFL. Geode Capital Management LLC lifted its stake in Rafael by 72.9% during the 2nd quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after acquiring an additional 190,179 shares during the period. Marshall Wace LLP bought a new stake in shares of Rafael in the second quarter worth approximately $50,000. Cable Car Capital LP bought a new stake in shares of Rafael in the second quarter worth approximately $173,000. Vanguard Group Inc. grew its stake in shares of Rafael by 10.5% in the third quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after acquiring an additional 133,024 shares during the period. Finally, Citadel Advisors LLC raised its holdings in shares of Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after purchasing an additional 41,335 shares during the last quarter. 11.30% of the stock is currently owned by institutional investors.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.